Wechselwirkungen · Yondelis
Yondelis 0.25 mg powder for concentrate for solution for infusion. Yondelis 1 mg powder for concentrate for solution for infusion. · Abschnitt 4.5 · PDF-Seite 7
HOS-117689 · Präparat HOS-094673
Since trabectedin is metabolised mainly by CYP3A4, the concentrations of trabectedin in plasma are likely to be increased in patients who are co-administered drugs that potently inhibit the activity of this isoenzyme. Similarly, the co-administration of trabectedin with potent inducers of CPY3A4 may increase the metabolic clearance of trabectedin. Two in vivo drug-drug interaction phase 1 studies have confirmed trends toward increased and decreased trabectedin exposures when administered with ketoconazole and rifampicin, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-20T12:25:00Z · SHA-256 ded6c974c7b3e49daa849909bad6cd80ddbd0729d218225406a5eca97ec9420a · Passage e4b4deeb92d55dcd5b14f32bd592f8abdf36c2083e604dc640edcbc11ec79ef1 · Zeichen 101–641 im Abschnitt